How the COVID-19 Vaccine for Children Differs From Adults’

 

Key Points:

  • Pfizer recently announced its vaccine for children is more than 90% effective.
  • In vitro diagnostics company Todos Medical announced the launch of their new COVID-19 antibody blood test which will allow unvaccinated and vaccinated people to monitor their immunity levels to the virus.
  • Healthcare professionals weigh the utility of this type of testing given the amount of at-risk people they interact with on a daily basis.

Commentary:

The next step in the fight against the COVID-19 virus has been the approval of the vaccine for children. Most recently, Pfizer announced that the vaccine that was approved for children is 90 percent effective against COVID-19. Now that the children’s vaccine is here, what was its development like compared to the one for adults? Was it easier or harder? We sat down with Gerald Commissiong, CEO of Todos Medical, to get insight into how the industry has approached the task of vaccine research and testing for different demographics.

MarketScale also asked Commissiong about the recent announcement by Todos about the launch of its new COVID-19 antibody blood test, which will allow unvaccinated and vaccinated people to monitor their immunity levels to the virus. What role will such a test play in the larger ecosystem of COVID treatment and mitigation?

Abridged Thoughts:

Initially, it was thought, although it’s not clear why it was thought, that children were not going to be affected by COVID in the same manner that adults were. As a result of that, the primary focus was really adults who were traveling from place to place, country to country who can spread the disease.

And the focus was on being able to really get people back into the office, back to work. What we found, obviously, is that getting back to work requires children to be able to get back to school. And so as we’ve made progress with the initial set of vaccines and really an undefined, unknown dosing schedule that has been figured out through real world decisions by different countries to do different things than the clinical trials, that kind of approach could have been disastrous in children because we know that their immune systems are not anywhere near as developed and that potentially impacting their immune systems in a robust way very early on in development could have significant long term impacts.

Because of that, I think correctly, everyone focused on developing an effective and safe vaccine for adults and then began to think through how to use the data from adults to develop for kids. There was some acceleration in the 12 to 15 year age gap with the Pfizer vaccine. I think that is being rethought extensively now, given some of the data and the younger kids where there is no evidence of myocarditis with a much lower dosing schedule that could potentially be even further reduced with lengthening the spacing between doses.

More Stories Like This:

Should the COVID-19 Vaccine’s Intellectual Property Be Accessible for Everyone?

Is It Time to Revamp the Drug Development Pipeline?

Follow us on social media for the latest updates in B2B!

Image

Latest

Brand experience with APL
Stepping into the Future at Shoptalk 2024: Creating a Flagship Brand Experience with APL
March 28, 2024

The customers of today are no longer satisfied with mere products; they crave brands that provide immersive, distinctive, and tailored brand experiences. Athletic Propulsion Labs (APL) epitomizes this shift, setting a new standard in the luxury performance market with its innovative athletic footwear. APL’s newly opened flagship boutique in Soho, with its artisan plaster walls […]

Read More
Balancing professional growth and personal well-being
Routines, Rituals and a Mission-Driven Approach: MarketScale’s CRO Tim Maitland on Balancing Professional Growth and Personal Well-Being
March 28, 2024

In a world that often demands the relentless pursuit of success, finding the sweet spot between professional growth and personal well-being can seem like an elusive goal. As we navigate the complexities of modern work-life dynamics, the conversation around maintaining this balance has become more pertinent than ever. In this episode of Growthwell, we […]

Read More
marketing careers
The Impact of AI on Marketing Careers
March 28, 2024

In this episode of The Marketing AI SparkCast, host Aby Varma, a B2B Marketing Leader and the Founder of Spark Novus, sits down with Matt Gill, the Founder and Managing Partner of MICA Consulting Group. Spark Novus is a consultancy specializing in strategic AI adoption in marketing. MICA is a leading boutique national marketing […]

Read More
healthcare cybersecurity
Continued Threats Require a Major Shift in Healthcare Cybersecurity Risk Perception
March 28, 2024

Recent cyberattacks on healthcare institutions have thrust cybersecurity from a back-office concern to the forefront of the healthcare industry’s agenda. A significant breach at Change Healthcare disrupted essential services, underlining the vulnerability of healthcare networks to such threats and the dire consequences for patient care. Government and industry responses have stressed the importance of […]

Read More